Legally Blind Artist Recovers Sight

May 26, 2014

His opthamologist at the University of British Columbia says he’s never seen anything like it. But Vancouver painter John Crittenden has beaten the odds (again) by taking a nutritional approach to heal an age-related form of blindness.

Crittenden, who has just turned 75, was diagnosed last year with “macular degeneration” in his right eye. The diagnosis was particularly devastating for him, given his lifelong career as a professional painter (Crittenden has produced and sold more than 1,200 paintings over a 48-year career, including an acclaimed portrait of the late Chief Dan George).


Three months later he had lost all sight in his right eye and the disease had started in the left one. His opthamologist said that he would never see again with his right eye. “I wasn’t prepared to accept that diagnosis,” said Crittenden. “So I began researching everything I could about the connection between diet and macular degeneration. I soon learned that most diseases have a basis in mineral deficiency, body acidity and a weak immune system.”

Faced with losing his sight completely, Crittenden developed his own naturopathic protocol that addresses the underlying causes of eye disease, including minerals, vitamins, amino acids and antioxidant deficiency plus lifestyle changes.

After eleven weeks the results have been dramatic. Crittenden’s vision has improved from 20/400 blindness to 20/50 vision—and he’s now planning to be back in his studio, hard at work on a new set of canvasses.

Crittenden’s opthamologist, Dr. Patrick Ma (who is a professor and current head of the Retina Division at the University of British Columbia), says he has never seen this kind of regeneration before and told John to “keep doing what you’re doing, you may change a lot of our minds.”

For more info:  John Crittenden
(604) 421-1085


Hi-tech glasses aim to assist the blind with directions and obstacle detection

May 23, 2014

Researchers from the Center for Research and Advanced Studies (CINVESTAV) in Mexico have developed a pair of glasses that use a combination of ultrasound, GPS, stereoscopic vision and artificial intelligence to help the visually impaired to navigate their environment. The device, perhaps the most sophisticated of its kind, is slated to reach mass production early next year and will likely cost up to US$1,500.
Prof. Bayro Corrochano’s team based the lenses’ technology on its previous work in robotic vision.
For more info:


Low Vision Readers = AMD reading glasses

May 17, 2014

Low Vision Readers give those with mild to moderate vision impairments the best possible chance of reading. This new technology overcomes the main factors which prevent individuals with low vision from reading – poor contrast and lighting and unrecognizable letters – by providing concentrated lighting, magnification, and prism correction. The combination of these elements permits some with low vision or vision impairment to read.


As one’s macular degeneration progresses there is a need for more magnification and more light. These special reading glasses combine the technology of concentrated lighting, magnification, and prism correction to offer a hands free reading aid.

For more info:  1-888-509-0910

Vasodilators associated with increased risk of age-related macular degeneration

May 9, 2014

1. After adjustments, use of vasodilators or ß-blockers were significantly associated with increased risk of early and late age-related macular degeneration (AMD), respectively.

2. In particular, oral nitroglycerin use was significantly associated with early AMD.

Evidence Rating Level: 2 (Good)

Study Rundown: Vasodilators are thought to stimulate the growth of subretinal vessels due to choroidal perfusion pressure. In this study, the investigators utilized the Beaver Dam Eye Study (BDES) data to assess the impact of various medications on age-related macular degeneration (AMD) risk. As indicated above, vasodilators (specifically oral nitroglycerin) and ß-blockers were found to have significant association with the development of AMD or progression of AMD. Strengths include the use of a strong database and rigorous statistical modeling. Limitations include the fact that these are associations; use of medications may not be causative, and the pathological mechanisms being treated by these medications (e.g., hypertension) may be somehow involved in the development of AMD. In addition, medications were self-reported, and thus may have been incorrect. Dosages of medications and consistency of administration were unavailable. Nonetheless, the study indicates that systemic medications may impact the development of AMD.

Click to read the study in Ophthalmology